EG 427 announces issuance of the first 2 patents for its HSV-based gene therapy treatment.

April 11, 2023
  • Issued European and Japanese patents cover herpes simplex virus (HSV) vectors selectively inhibiting subtype of sensory neurons
  • Related initial therapeutic indications encompass multiple bladder conditions with a first focus on neurogenic detrusor overactivity 

Read full press release in English or in French


Recent posts

EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters
EG 427 Appoints Don Haut, Ph.D as Chief Business Officer and Opens US Headquarters

read more >

EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder
EG 427 Announces Positive Preclinical Results from EG110A IND-Enabling Study in Neurogenic Detrusor Overactivity and Overactive Bladder

read more >

EG 427 to hold poster presentation on lead asset EG110A at ESGCT
EG 427 to hold poster presentation on lead asset EG110A at ESGCT

read more >

EG 427 announces attendance to multiple upcoming conferences in fall 2023
EG 427 announces attendance to multiple upcoming conferences in fall 2023

read more >

EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting
EG 427 presents positive preclinical data on lead asset EG110A at International Continence Society meeting

read more >

×

Essential Cookies

These cookies are necessary for the website to function and cannot be turned off. They are used, for example, to maintain the contents of the user's basket. You can set your browser to block these cookies, but then the website will not function prope

Always active

Analytical cookies

These cookies allow you to count visits and traffic sources. Thanks to these files, it is known which pages are more popular and how the website visitors navigate. All information these cookies collect is anonymous.